General Motors (GM) made a splash today by announcing that Mary Barra would become its next CEO. Barra would be the first woman to ever lead a U.S. automaker, and while the excitement wasn’t reflected in a slightly retreating GM stock price, this is a noteworthy breakthrough for an industry with a macho, rough-around-the-edges image.
Top 10 Chemical Companies To Invest In Right Now: Organovo Holdings Inc (ONVO)
Organovo Holdings, Inc. (Organovo), formerly Real Estate Restoration & Rental, Inc., incorporated in 2007, is a development-stage company. The Company has developed and is commercializing a platform technology for the generation of three-dimensional (3D) human tissues that can be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs. On December 28, 2011, Real Estate Restoration and Rental, Inc.�� (RERR) entered into an Agreement and Plan of Merger, pursuant to which RERR merged with its, wholly owned subsidiary, Organovo (Merger Sub). On February 8, 2012, the Company merged with and into Organovo Acquisition Corp. (Acquisition Corp.), a wholly owned subsidiary of Organovo, with the Company surviving the merger as a wholly owned subsidiary of Organovo Holdings (the Merger). As a result of the Merger, Organovo acquired the business of Organovo, Inc.
The Company has collaborative research agreements with Pfizer, Inc. (Pfizer) and United Therapeutic Corporation (Unither). As of March 31, 2012, it has five federal grants, including Small Business Innovation Research grants and developed the NovoGen MMX Bioprinter (its first-generation 3D bioprinter). The Company is engaged in the development of specific 3D human tissues to aid Pfizer in discovery of therapies in two areas of interest. In addition, in October 2011, it entered into a research agreement with Unither to establish and conduct a research program to discover treatments for pulmonary hypertension using its NovoGen MMX Bioprinter technology. Additionally, under the research agreement with Unither, the Company granted Unither an option to acquire from the Company a worldwide, royalty-bearing license in certain intellectual property created under the research agreement solely for use in the treatment or prevention of pulmonary hypertension and all other lung diseases.
The Company�� NovoGen MMX Bioprinter is an automate! d device that enables the fabrication of three-dimensional (3D) living tissues comprised of mammalian cells. A custom graphic user interface (GUI) facilitates the 3D design and execution of scripts that direct precision movement of the dispensing heads to deposit cellular building blocks (bio-ink) or supporting hydrogel. The Company is using a third party manufacturer, Invetech Pty., of Melbourne, Australia, to manufacture its NovoGen MMX Bioprinter. Its bioprinting technology and surrounding intellectual property and commercial rights serve as a platform for product generation across multiple markets that employ cell- and tissue-based products and services.
The Company competes with Organogenesis, Advanced BioHealing, Tengion, Genzyme, HumaCyte and Cytograft Tissue Engineering.
Advisors' Opinion:- [By FinanceGuru]
Shares of almost all 3D printing companies have appreciated considerably this year. Even though analysts are expecting 3D printing to be worth more than $5 billion by 2018, I don't think investing in 3D printing companies, mainly 3D Systems (DDD), is a good idea. Investors have bid up 3D Systems in the hope that its technology will revolutionize the industrial manufacturing process and it will also have a massive presence in the consumer segment. However, I don't think that 3D Systems will be able to fulfill these expectations any time soon, and it may take many years to justify its valuation. Therefore, in my view, investors who want to see good returns in the long run should invest their money in Organovo (ONVO) rather than 3D Systems. Let's take a look why.
- [By Roberto Pedone]
Organovo (ONVO) is a three-dimensional biology company focused on delivering breakthrough bioprinting technology and creating tissue on demand for research and medical applications. This stock closed up 8.5% to $5.21 in Thursday's trading session.
52-Week Range: $1.78-$8.50
Thursday's Volume: 2.88 million
Three-Month Average Volume: 1.78 millionFrom a technical perspective, ONVO ripped higher here back above its 50-day moving average of $4.88 with heavy upside volume. This stock has been downtrending badly for the last month, with shares plunging lower from its high of $8.50 to its recent low of $4.43. During that downtrend, shares of ONVO have been consistently making lower highs and lower lows, which is bearish technical price action. That said, shares of ONVO might be ready to see its downside volatility stop and reverse its downtrend and enter a new uptrend. The probability for that reverse in trend is supported by the high volume on Thursday.
Traders should now look for long-biased trades in ONVO as long as it's trending above its recent low at $4.33 and then once it sustains a move or close above $5.21 to $5.64 with volume that hits near or above 1.78 shares. If we get that move soon, then ONVO will set up to re-test or possibly take out its next major overhead resistance levels at $6.65 to $7.50.
- [By James E. Brumley]
If you're looking for some trading action, then Organovo Holdings Inc. (NYSEMKT:ONVO) and Albemarle Corporation (NYSE:ALB) are the two top names to put on your radar today. Granted, they're trading candidates for completely opposing reasons. In fact, the best "play" may be to swap one for the other. However you want to play it though, here's what you need to know about ALB and ONVO.
Top Integrated Utility Stocks To Watch For 2015: S&P GSCI(GD)
General Dynamics Corporation, an aerospace and defense company, provides business aviation; combat vehicles, weapons systems, and munitions; military and commercial shipbuilding; and communications and information technology products and services worldwide. Its Aerospace group designs, manufactures, and outfits various large and mid-cabin business-jet aircraft; provides maintenance, repair work, fixed-based operations, and aircraft management services; and performs aircraft completions for aircraft. The company?s Combat Systems group offers tracked and wheeled military vehicles, weapons systems, and munitions. Its product lines include wheeled combat and tactical vehicles; battle tanks and infantry vehicles; munitions and propellant; rockets and gun systems; and axle and drivetrain components and aftermarket parts. This group also manufactures and supplies engineered axles, suspensions, and brakes for heavy-load vehicles for military and commercial customers. The company Advisors' Opinion:
- [By Rich Smith]
General Dynamics (NYSE: GD ) �won a $67.4 million Pentagon contract Thursday, the Pentagon has just confirmed. Curiously, though, the General Dynamics division that won the award may soon not exist -- at least not independently.
- [By Rich Smith]
On Friday, the U.S. Department of Defense announced it has awarded General Dynamics' (NYSE: GD ) Electric Boat Corp. subsidiary a $208.6 million "undefinitized" contract modification to a previously awarded contract. The funds are to be used to purchase long-lead-time materials needed for construction of three Virginia-class nuclear fast attack submarines:
- [By Ben Levisohn]
Last quarter, Buffett sold his stakes in�Archer Daniels Midland�(ADM) and�General Dynamics�(GD), and added to a position�in�International Business Machines�(IBM). He also bought shares of�Chicago Bridge & Iron�(CBI), an old favorite of mine from my trading days.�
- [By Charles Mizrahi]
General Dynamics (GD) offers segment diversification. Although the US government accounts for nearly two-thirds of the company's revenue, it has four operating segments, with no single division accounting for more than a third of total revenue.
Top Integrated Utility Stocks To Watch For 2015: SurModics Inc.(SRDX)
SurModics, Inc. provides drug delivery and surface modification technologies to the healthcare industry. The company offers surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices, as well as drug delivery coating technologies to provide site-specific drug delivery from the surface of a medical device for the coronary, peripheral, neuro-vascular, and urology markets. It also provides a range of drug delivery technologies for injectable therapeutics, including microparticles, nanoparticles, and implants addressing a range of clinical applications, such as ophthalmology, oncology, dermatology, and neurology. In addition, the company provides in vitro diagnostic component products and technologies comprising microarray slide technologies, protein stabilization reagents, substrates, polymers and reagent chemicals, and antigens for diagnostic test kits and biomedical research applications. SurModics, Inc. market s its technologies and products worldwide through direct sales force consisting of sales professionals. The company was founded in 1979 and is headquartered in Eden Prairie, Minnesota.
Advisors' Opinion:- [By Seth Jayson]
Calling all cash flows
When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on SurModics (Nasdaq: SRDX ) , whose recent revenue and earnings are plotted below. - [By Seth Jayson]
Calling all cash flows
When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on SurModics (Nasdaq: SRDX ) , whose recent revenue and earnings are plotted below.
Top Integrated Utility Stocks To Watch For 2015: OncoSec Medical Inc (ONCS)
OncoSec Medical Incorporated, incorporated on February 8, 2008, is an emerging drug-medical device company. The Company focused on designing, developing and commercializing medical approaches for the treatment of solid cancers. In March 2011, the Company acquired from Inovio Pharmaceuticals, Inc. (Inovio) certain assets related to the use of drug-medical device combination products for the treatment of different cancers.
The Company�� acquired assets relate to certain non-deoxyribonucleic acid (DNA) vaccine technology and property relating to selective tumor ablation technologies, which it refers to as the OncoSec Medical System (OMS), a therapy which uses an electroporation device to facilitate delivery of chemotherapy agents, or nucleic acids encoding cytokines, into tumors and/or surrounding tissue for the treatment and diagnosis of various cancers. As of January 24, 2012, the Company had not generated any revenue from operations.
Advisors' Opinion:- [By John Udovich]
Small cap biotech stocks AVEO Pharmaceuticals, Inc (NASDAQ: AVEO), OncoSec Medical Inc (OTCMKTS: ONCS) and MetaStat Inc (OTCBB: MTST) are focused on or are developing treatments or diagnostic technologies for metastatic cancers. In case you aren�� familiar with the term metastasis or metastatic, it�� the�spread of cancer from its primary site to other places in the body as cancer cells break away from a primary tumor, penetrate into lymphatic and blood vessels, circulate through the bloodstream and then grow in a new focus (metastasize) in normal tissues elsewhere in the body. In other words, it�� a dangerous form of cancer, but there are some small cap biotech stocks targeting it for diagnostics or treatment:
- [By Bio-Wire]
Another company that has benefitted from Inovio�� newfound attention is OncoSec Medical (OTC: ONCS) ��a newer ��ffshoot�� company that uses a similar but distinctly different electroporation device known as the OncoSec Medical System (OMS) that is based on Inovio�� technology. The specific amplitude and frequency of the OMS electroporation is calibrated such that plasmid delivery into solid tumor masses is fully optimized, while CELLECTRA electroporation is less specialized and focus more on the vaccination of skin cells. The cross-license agreement made between Inovio and Oncosec also covers the two devices for their distinctly different applications.
- [By James E. Brumley]
If you're looking for the next big biotech breakout stock, then OncoSec Medical Inc. (OTCMKTS:ONCS) deserves a place on your watchlist. This volatile cancer play has been down more than up 2011, but if you look closely at a long-term chart of ONCS, you may find it's already wiggled its way into a new uptrend. And, it may be only a matter of time before the bullish fireworks start to go off.
Top Integrated Utility Stocks To Watch For 2015: Players Network (PNTV)
Players Network (PNTV), incorporated on March 16, 1993, is a global media and entertainment company engaged in the development of Digital Networks. The Company distributes broadband video and other social media content over a range of Internet enabled devices and cable television channels. The Company�� platform is designed to deliver video content and develop digital social communities, including Vegas On Demand TV. The Company operates a video on demand (VOD) television channel, also named Vegas On Demand, which consists of original programming that is distributed over its own VOD channels to approximately 24,000,000 homes over the Internet with distribution partners, which include, Comcast, Hulu, Blinkx, Google, and YouTube Video, for DVD home video, and various mobile platforms. Vegas On Demand TV offers its audience the ability to connect to Vegas Insiders through programming, which captures sex appeal, entertainment, and the non-stop adrenaline rush of the Las Vegas gaming lifestyle. Players Network�� content goes beyond poker, casino action, sports betting, and racing, to lifestyle programs about entertainment and fine living.
PNTV�� Media Network operates across all distribution platforms from television screens to mobile devices, gaming consoles, computers and tablets. The Company�� platform has two main membership categories: the Consumer/User who visits its digital communities and partakes in viewing ad-supported and pay-per-view premium videos, purchases products and connects with Insiders, who are its Premium Members. Players Network�� Programming Brands include Vegas On Demand focuses on Gaming lifestyle and produces programming about Horse Racing, Sports Betting, Casino Games and Poker; Vegas On Demand, which is about Las Vegas lifestyle and covers celebrity, night clubs, poolside experiences and entertainment, and Sexy Sin City TV covers the adult and sexy side of Las Vegas after dark. The Company�� productions include gaming instruction, gaming news, instruct! ion on sports and racing wagering, gaming entertainment, tournaments, events and travel. The Company has a library of 1,550 gambling and gaming lifestyle videos, including several series of both long and short form content. Some of these series include Players Network originals; Hidden Vegas, Tattoo Tails, which include 30 originally produced hours of programming from the World Series of Poker, which Players Network had the rights to produce and air live. Players Network produced over 50 videos at the Hooters Hotel and Casino, 28 new gaming instructional videos aimed at slots and video poker players, a series of 23 videos on magic entitled Hocus Pocus, The Best of Vegas series and Neon Buzz, an entertainment report which covered red carpet events.
The Company competes with ESPN, the Travel Channel, E! and the Food Network.
Advisors' Opinion:- [By Peter Graham]
Small cap entertainment or gaming stocks Soul and Vibe Interactive Inc (OTCBB: SOUL), Elray Resources Inc (OTCMKTS: ELRA) and Players Network (OTCMKTS: PNTV) focus on entertaining consumers. However, its important to remember that consumers can be very fickle when it comes to entertainment or games. So should you be entertaining any of these small caps? Here is a closer look and a reality check:
Top Integrated Utility Stocks To Watch For 2015: Prothena Corporation PLC (PRTA)
Prothena Corporation PLC, incorporated on September 26, 2012, is an Ireland-based, clinical-stage biotechnology company. The Company is engaged in discovering and developing monoclonal antibodies that are directed towards misfolded proteins or improper cell adhesion. Its pipeline includes NEOD001, PRX002 and PRX003. The Company�� work in protein misfolding could result in therapies to treat several neurodegenerative diseases, including AL (primary) and AA (secondary) forms of amyloidosis (NEOD001), Parkinson's disease and related synucleinopathies (PRX002). Its cell adhesion development activities could generate new therapies to treat inflammatory diseases and metastatic cancers (PRX003). The Company�� program, NEOD001, is in Phase 1. In addition to antibodies directed to neo-epitope targets, it is developing antibodies directed to other targets. The Company has generated antibodies against cell adhesion targets expressed on certain pathogenic Th17 immune cells and tumor cells.
The Company�� pipeline also includes several late discovery stage programs for which it is testing antibodies in preclinical models of disease. It is also generating additional antibodies against other targets involved in protein misfolding and cell adhesion for characterization in vivo and in vitro.
NEOD001 for Amyloidosis
NEOD001 is a monoclonal antibody that targets the amyloid that accumulates in both AL and AA forms of amyloidosis. The antibody was designed to not react with normal serum amyloid A and only with the aberrant cleaved form of the protein (amyloid A).
PRX002 for Parkinson�� Disease
The Company has generated antibodies targeting alpha-synuclein that may slow or reduce the neurodegeneration associated with synuclein misfolding and/or transmission. It has tested these antibodies in various cellular and animal models of synuclein-related disease. In a transgenic mouse model of Parkinson�� disease, passive immunization with 9E4, a murine ver! sion of PRX002, reduced the appearance of synuclein pathology, protected synapses and improved performance by the mice in behavioral testing. The humanized antibody product candidate PRX002 has advanced into manufacturing and preclinical testing.
PRX003 for Inflammatory Diseases and Cancers
The Company is developing PRX003, a monoclonal antibody targeting MCAM for the potential treatment of inflammatory diseases and cancers. It has generated monoclonal antibodies that block MCAM-mediated cell adhesion and have been shown to delay relapse and severity of relapse in a mouse model of multiple sclerosis known as experimental autoimmune encephalomyelitis. The Company�� antibodies are being tested in animal models of inflammatory diseases and cancers. Based on early results from these studies, it has identified a clinical candidate, PRX003. It has advanced this antibody into manufacturing and intends to advance this antibody into preclinical testing.
Advisors' Opinion:- [By Jake L'Ecuyer]
Equities Trading UP
Prothena Corporation plc (NASDAQ: PRTA) shares shot up 21.60 percent to $45.19 after the company reported clinical data to be presented at International Symposium on Amyloidosis. Morgan Stanley raised the price target on the stock from $35.00 to $53.00.
Top Integrated Utility Stocks To Watch For 2015: Vivendi SA (VIVHY)
Vivendi SA (Vivendi), incorporated on December 18, 1987, is a communications and entertainment company. As of December 31, 2009, the Company had six business segments: Activision Blizzard, Universal Music Group, SFR, Maroc Telecom Group, GVT (Holding) S.A. (GVT) and Canal+ Group. Activision Blizzard develops, publishes and distributes interactive entertainment software, online or on other media (such as console and personal computer (PC)). Universal Music Group is engaged in the sale of recorded music (physical and digital media), exploitation of music publishing rights, as well as artist services and merchandising. SFR is engaged in the phone services (mobile, broadband Internet and fixed) in France. Maroc Telecom Group is a telecommunication operator (mobile, fixed and Internet) in Africa, principally in Morocco, as well as in Mauritania, Burkina Faso, Gabon and Mali. GVT is a Brazilian fixed and broadband operator. Canal+ Group is engaged in publishing and distribution of pay-television mainly in France, in both analog and digital (terrestrially, via satellite or ADSL), as well as film production in Europe. In July 2013, Vivendi SA and Universal Music Group announced the completion of the sale of Parlophone Label Group to Warner Music Group Corp.
On November 13, 2009, Vivendi acquired an aggregate of 29.9% of GVT�� outstanding voting shares from Swarth Investments LLC, Swarth Investments Holdings LLC and Global Village Telecom (Holland) BV. In addition, Vivendi acquired from third parties an additional 8% interest in GVT's outstanding shares. On December 28, 2009, Canal+ Group, Vivendi�� subsidiary, acquired TF1�� 9.9% interest in the capital of Canal+ France. On July 31, 2009, Maroc Telecom acquired 51% controlling interest in Sotelma. On August 27, 2009, CID, a company 40% owned by SFR and 60% by other financial investors, acquired the 62% interest in 5 sur 5.
Advisors' Opinion:- [By Demitrios Kalogeropoulos]
Activision Blizzard (NASDAQ: ATVI ) is striking out on its own. The company reached a purchase agreement with Vivendi (NASDAQOTH: VIVHY ) �to transfer enough shares so that it will become an independent company, one that's majority-owned by public investors rather than a single corporation.
No comments:
Post a Comment